Five Ways the 2026 National Cancer Plan Could Shape the Future of Early Cancer Detection

The UK Government’s National Cancer Plan for England sets out an ambitious vision for improving cancer outcomes over the next decade. At its core is a clear objective: by 2035, three in four people diagnosed with cancer should survive for at least five years, supported by earlier diagnosis, faster treatment and greater access to innovation.

While the plan covers prevention, treatment, research and survivorship, one of its strongest themes is the transformation of early cancer detection. Rather than relying solely on existing pathways, it outlines how new technologies, data and personalised approaches could reshape the way cancer is identified across England.

Here are five developments that stand out.

1. Earlier Diagnosis Is at the Heart of the Strategy

Earlier diagnosis is no longer presented as one element of cancer care—it is positioned as one of the central drivers of improving long-term survival.
The plan commits to increasing the proportion of cancers diagnosed at an earlier stage, alongside improving diagnostic pathways and reducing waiting times. This reflects growing recognition that identifying cancer before it progresses can provide patients with more treatment options and improve overall outcomes.

2. Innovation Is Becoming Part of Mainstream Cancer Policy

The National Cancer Plan places significant emphasis on accelerating innovation across the NHS.

This includes expanding access to genomic technologies, artificial intelligence and advanced diagnostics, while creating clearer pathways for evaluating and adopting promising new technologies. Rather than viewing innovation as separate from routine care, the plan presents it as an essential part of modernising cancer services.

3. Blood-Based Tests Are Moving Further Into the Conversation

One of the most notable aspects of the plan is its recognition of emerging blood biomarker technologies, including multi-cancer early detection (MCED) tests.

The document does not recommend widespread implementation today. Instead, it supports continued evaluation to determine where these technologies may provide clinical benefit and how they could complement existing screening programmes in the future. This evidence-led approach reflects the importance of demonstrating accuracy, clinical effectiveness and value before introducing new screening tools at population level.

4. Personalised Screening Is Becoming a Greater Focus

Traditional screening programmes are generally based on age and population-level risk.

The National Cancer Plan signals a gradual move towards more personalised approaches by highlighting genomics, risk assessment and data-driven decision making. As scientific understanding continues to develop, future screening pathways may increasingly consider an individual’s biological and genetic risk alongside conventional eligibility criteria.

5. Validation Remains Essential

Perhaps the most important message within the plan is that innovation alone is not enough.

New diagnostic technologies must demonstrate robust clinical evidence before they can become part of routine healthcare. Throughout the document, there is a clear emphasis on evaluation, validation and ensuring that new approaches improve outcomes while delivering value for patients and the NHS.

RMDM’s Perspective

At RMDM, we welcome the National Cancer Plan’s focus on earlier diagnosis and the continued evaluation of innovative diagnostic technologies.

PanTum Detect is a CE-marked, blood-based screening test built on EDIM (Epitope Detection in Monocytes) technology. By analysing the tumour-associated biomarkers TKTL1 and Apo10 within monocytes, it represents a different scientific approach to blood-based cancer detection, focusing on tumour metabolism and immune-cell biology rather than circulating tumour DNA.

As the UK’s cancer strategy continues to evolve, we believe that rigorously validated diagnostic technologies will play an increasingly important role in supporting earlier detection. Equally important is ensuring that each innovation is supported by robust clinical evidence and integrated into healthcare pathways where it can provide meaningful benefit for patients.

Looking Ahead

The National Cancer Plan does not represent the end of the conversation about early cancer detection—it marks the beginning of the next phase.

By combining investment in research, improved diagnostic pathways and careful evaluation of emerging technologies, the plan sets out a framework for how cancer detection may evolve over the coming decade.

For organisations working at the forefront of oncology diagnostics, the direction is clear: earlier detection, stronger clinical evidence and continued innovation will remain central to improving cancer outcomes across the UK.

References

1. Department of Health and Social Care & NHS England. The National Cancer Plan for England. Published 4 February 2026.
2. Department of Health and Social Care & NHS England. The National Cancer Plan for England: Delivering World Class Cancer Care. Published February 2026.
3. Cancer Research UK. A Turning Point for Cancer? Breaking Down the National Cancer Plan for England. Published 4 February 2026.